Introduction
NSCLC, C797S mutation [
NON-SMALL CELL LUNG CANCER, SOMATIC MUTATION, NSCLC
Molecularly targeted therapies have emerged as essential treatment modalities for non-small cell lung cancer (NSCLC). Somatic mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain have been reported as definitive biomarkers for predicting the efficacy of The mechanisms underlying osimertinib resistance can be divided into Interestingly, preclinical data suggest that treatment with a combination of osimertinib and first/second-generation EGFR-TKIs can overcome the acquired C797S mutation [